Efruxifermin in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a trial
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Efruxifermin in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a trial
Authors
Keywords
-
Journal
NATURE MEDICINE
Volume 27, Issue 7, Pages 1262-1271
Publisher
Springer Science and Business Media LLC
Online
2021-07-09
DOI
10.1038/s41591-021-01425-3
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Therapeutic landscape for NAFLD in 2020
- (2020) Brent A. Neuschwander-Tetri GASTROENTEROLOGY
- Efficacy and Safety of Aldafermin, an Engineered FGF19 Analog, in a Randomized, Double-Blind, Placebo-Controlled Trial of Patients With Nonalcoholic Steatohepatitis
- (2020) Stephen A. Harrison et al. GASTROENTEROLOGY
- The therapeutic potential of FGF21 in metabolic diseases: from bench to clinic
- (2020) Leiluo Geng et al. Nature Reviews Endocrinology
- FGF21: An Emerging Therapeutic Target for Non-Alcoholic Steatohepatitis and Related Metabolic Diseases
- (2020) Erik J. Tillman et al. Frontiers in Endocrinology
- 140-LB: NGM313, a Novel Activator of b-Klotho/FGFR1c, Improves Insulin Resistance and Reduces Hepatic Fat in Obese, Nondiabetic Subjects
- (2019) ALEX DEPAOLI et al. DIABETES
- Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
- (2019) Stephen A Harrison et al. LANCET
- Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial
- (2019) Zobair M Younossi et al. LANCET
- NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
- (2018) Stephen A Harrison et al. LANCET
- A Common Allele in FGF21 Associated with Sugar Intake Is Associated with Body Shape, Lower Total Body-Fat Percentage, and Higher Blood Pressure
- (2018) Timothy M. Frayling et al. Cell Reports
- Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial
- (2018) Arun Sanyal et al. LANCET
- Pegbelfermin (BMS-986036), PEGylated FGF21, in Patients with Obesity and Type 2 Diabetes: Results from a Randomized Phase 2 Study
- (2018) Edgar D. Charles et al. Obesity
- A Novel Fc-FGF21 With Improved Resistance to Proteolysis, Increased Affinity Toward β-Klotho, and Enhanced Efficacy in Mice and Cynomolgus Monkeys
- (2017) Shanaka Stanislaus et al. ENDOCRINOLOGY
- The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases
- (2017) Naga Chalasani et al. HEPATOLOGY
- A Long-Acting FGF21 Molecule, PF-05231023, Decreases Body Weight and Improves Lipid Profile in Non-human Primates and Type 2 Diabetic Subjects
- (2016) Saswata Talukdar et al. Cell Metabolism
- Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes
- (2016) Zobair M. Younossi et al. HEPATOLOGY
- Association of noninvasive quantitative decline in liver fat content on MRI with histologic response in nonalcoholic steatohepatitis
- (2016) Janki Patel et al. Therapeutic Advances in Gastroenterology
- Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis
- (2015) Eduardo Vilar-Gomez et al. GASTROENTEROLOGY
- The Enhanced liver fibrosis score is associated with clinical outcomes and disease progression in patients with chronic liver disease
- (2015) Katharine M. Irvine et al. LIVER INTERNATIONAL
- Markers of Collagen Remodeling Detect Clinically Significant Fibrosis in Chronic Hepatitis C Patients
- (2015) Mette J. Nielsen et al. PLoS One
- Opposite alterations in FGF21 and FGF19 levels and disturbed expression of the receptor machinery for endocrine FGFs in obese patients
- (2014) J M Gallego-Escuredo et al. INTERNATIONAL JOURNAL OF OBESITY
- The Effects of LY2405319, an FGF21 Analog, in Obese Human Subjects with Type 2 Diabetes
- (2013) Gregory Gaich et al. Cell Metabolism
- Increased De Novo Lipogenesis Is a Distinct Characteristic of Individuals With Nonalcoholic Fatty Liver Disease
- (2013) Jennifer E. Lambert et al. GASTROENTEROLOGY
- Uric Acid Induces Hepatic Steatosis by Generation of Mitochondrial Oxidative Stress
- (2012) Miguel A. Lanaspa et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Adiponectin Regulation of Stellate Cell Activation via PPARγ-Dependent and -Independent Mechanisms
- (2011) Mahnoush S. Shafiei et al. AMERICAN JOURNAL OF PATHOLOGY
- Prevalence of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis Among a Largely Middle-Aged Population Utilizing Ultrasound and Liver Biopsy: A Prospective Study
- (2010) Christopher D. Williams et al. GASTROENTEROLOGY
- Association between serum uric acid level and chronic liver disease in the United States
- (2010) Anita Afzali et al. HEPATOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now